The baseline risk of HZ in rheumatoid arthritis is 1.5–2-fold higher compared to the general population, and the incidence of HZ reported with tofacitinib, which preferentially inhibits JAK1, JAK2, and JAK3, is double that reported in RA (25). The gene discussed is JAK3; the disease is rheumatoid arthritis.